Daniel A. Filippa

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz et al. · Blood · 2001 · 423 citations · Full text

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer et al. · Blood · 2004 · 403 citations · Full text

Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma

Kenneth Offit, Francesco Lo‐Coco, Diane C. Louie et al. · New England Journal of Medicine · 1994 · 378 citations · Full text

Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

Craig H. Moskowitz, Heiko Schöder, Julie Teruya‐Feldstein et al. · Journal of Clinical Oncology · 2010 · 324 citations · Full text

Progression-free Survival, Immunology, Pathology +18

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

Craig H. Moskowitz, Joseph R. Bertino, Jill R. Glassman et al. · Journal of Clinical Oncology · 1999 · 302 citations